Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EuroapiXPAR:EAPI +0.61%54 Future 3-5Y EPS without NRI Growth Rate is 76.61 as of Aug. 13, 2026. GuruFocus rates XPAR:EAPI with a GF Score™ of 54/100 and a GF Value™ of €2.84 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 66 Drug Manufacturers companies, Euroapi ranks worse than 1515150% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Euroapi's Future 3-5Y EPS without NRI Growth Rate is 76.61.
Euroapi (XPAR:EAPI) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Euroapi Future 3-5Y EPS without NRI Growth Rate Related Terms
XPAR:EAPI vs ZTS, UTHR, VTRS: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euroapi Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euroapi's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Euroapi's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 76.61 mean?
Euroapi (XPAR:EAPI) has a Future 3-5Y EPS without NRI Growth Rate of 76.61 as of Aug. 13, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Euroapi and its competitors. According to the industry distribution chart, Euroapi ranks #999999 out of 66 companies in the Drug Manufacturers industry.
Is Euroapi's Future 3-5Y EPS without NRI Growth Rate too high?
Euroapi's current Future 3-5Y EPS without NRI Growth Rate is 76.61. The Drug Manufacturers industry median Future 3-5Y EPS without NRI Growth Rate is 14.20. Euroapi's value of 76.61 is 439.7% above this industry median. Based on the distribution chart, Euroapi ranks #999999 out of 66 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Euroapi has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's Future 3-5Y EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euroapi ranks #999999 out of 66 companies for Future 3-5Y EPS without NRI Growth Rate. This places Euroapi in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 14.20. Euroapi's value of 76.61 is 439.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Drug Manufacturers company?
The median Future 3-5Y EPS without NRI Growth Rate among Drug Manufacturers companies is 14.20, based on 66 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euroapi's current Future 3-5Y EPS without NRI Growth Rate of 76.61 is 439.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Euroapi and its competitors. For the Drug Manufacturers industry, the median Future 3-5Y EPS without NRI Growth Rate is 14.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroapi's current Future 3-5Y EPS without NRI Growth Rate is 76.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.84, compared to a current price of €1.00 — trading 64.9% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 76.61 and 439.7% above the Drug Manufacturers industry median of 14.20. Euroapi's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current Future 3-5Y EPS without NRI Growth Rate is 76.61 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euroapi (XPAR:EAPI) Overvalued in 2026?
Based on GuruFocus' analysis, Euroapi stock appears to be undervalued.
The current stock price of €1.00 is trading 64.9% below its estimated GF Value™ of €2.84.
GuruFocus considers Euroapi to be Possible Value Trap.
Key valuation signals for XPAR:EAPI:
Future 3-5Y EPS without NRI Growth Rate: 76.61
GF Value™: €2.84 vs. price of €1.00 (64.9% below fair value)
Industry Position: 439.7% above the Drug Manufacturers median (#999999 of 66)
No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
54GF Score
Get the complete analysis for XPAR:EAPI
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:EAPI has been successfully added to your 
